High Dose Chemotherapy (HDT) with Busulfan, Melphalan and Topotecan Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) in Pediatric Patients (pts) with High Risk Solid Tumors  by Pawlowska, A.B. et al.
Poster Session I S249matching pairs. The primary clinical outcomes were time to progres-
sion (TTP), progression-free survival (PFS), and overall survival
(OS), all defined from the time of auto-HCT. Stratified Log-rank
test and Cox proportional hazards model stratified on matched pairs
were conducted on TTP, PFS and OS.
Results: Patient characteristics are summarized in the attached
Table. NSM and SM groups were not different by age at auto-
HCT, time from diagnosis to auto-HCT, race, sex, and serum
creatinine at auto-HCT (Table). Patients with SM had higher
percentage of bone marrow plasma cells at auto-HCT. Median
follow-up time was 37 months. Median TTP was 29 months and
31 months for the NSM and SM groups, respectively. Median
PFS was 16 months and 29 months for the NSM and SM groups,
respectively. Median OS was 45 and 67 months in the NSM and
SM groups, respectively. There was no difference in TTP, PFS
and OS between NSM and SM after adjusting for conditioning
regimen or time from diagnosis to transplant in the multivariate
models (p-Value .0.69).
Conclusion: In this large single center study the outcome of pa-
tients with NSM was comparable to patients with SM after an
auto-HCT.
Table. Association between patients characteristics and
histology
Covariate Levels NSM SM p-ValueAge at diagnosis age< 5 54.25 (median) 17 (54.8%) 45 (47.9%) 0.478age>54.25 14 (45.2%) 49 (52.1%)Age at transplant age < 5 55.17(median) 17 (54.8%) 45 (47.9%) 0.4625age >55.17 14 (45.2%) 49 (52.1%)Age at transplant <40 1 (3.2%) 2 (2.1%) 0.807240-49 7 (22.6%) 24 (25.5%)50-59 16 (51.6%) 48 (51.1%)> 5 60 7 (22.6%) 20 (21.3%)Time from diagnosis
to transplant>8months 12 (38.7%) 43 (45.7%) 0.2863< 5 8 months 19 (61.3%) 51 (54.3%)Racial Group Black 3 (9.7%) 11 (12%) 0.2849Mixed 4 (12.9%) 25 (27.2%)White 24 (77.4%) 56 (60.9%)Sex F 14 (45.2%) 34 (36.2%) 0.3010M 17 (54.8%) 60 (63.8%)Plasmacytoma No 24 (77.4%) 70 (75.3%) 0.7646Yes 7 (22.6%) 23 (24.7%)Creatinine < 5 1 13 (52%) 36 (48%) 0.3242>1 12 (48%) 39 (52%)Plasma cell%
pre-transplant< 5 10% 9 (34.6%) 14 (17.5%) 0.0561>10% 17 (65.4%) 66 (82.5%)122
PEGFILGRASTIM VS FILGRASTIM-BASED STEADY STATE AUTOLOGOUS
HSC MOBILIZATION IN THE SETTING OF PATIENT ADAPTED (‘‘JUST IN
TIME’’) PLERIXAFOR: EFFICACY AND ECONOMIC OUTCOMES
Costa, L.J., Kramer, C., Hogan, K.R., Butcher, C.D., Littleton, A.,
Shoptaw, K.B., Kang, Y., Stuart, R.K. Medical University of South Car-
olina, Charleston, SC
Plerixafor enhances the ability of filgrastim to mobilize CD34+
cells for AHSCT in patients with lymphoma (LY) or multiple my-
eloma (MM). Single dose of pegfilgrastim has, in some series,
been utilized for autologous mobilization for its convenience
and possibly greater efficacy. We retrospectively compared two
consecutive mobilization cohorts utilizing filgrastim (FIL) 10
mcg/kg/day or pegfilgrastim (PEG) 12 mg (single dose) for steady
state mobilization and the same algorithm for ‘‘just in time’’ use of
plerixafor. In both cohorts peripheral blood CD34+ cells (PB-
CD34+) enumeration was performed on the 4th day after initia-
tion of growth factor to determine the immediate initiation of
apheresis or administration of plerixafor with apheresis starting
in the next day. Decision to use plerixafor was determined by
the same previously validated algorithm in both cohorts. Apheresis
and growth factor +/- plerixafor were continued until the mobili-
zation target was met. Analysis of estimated total cost of mobili-zation utilized average wholesale price (AWP) for drugs and
average charges for apheresis, cryopreservation and laboratory
tests from a representative sample of subjects. Seventy-four con-
secutive subjects were included in FIL and 57 in PEG. The two
cohorts were comparable in terms of age (57.5 vs. 53.7), propor-
tion of patients with diagnosis of MM (63.5% vs.66.7%), propor-
tion of MM patients previously exposed to lenalidomide (63.8%
vs. 50%), average body weight (82.9 vs.84 kg) and average mobi-
lization target (4.5 vs. 5 x 106 CD34+/kg). Overall 68/74 in FIL
and 52/57 patients in PEG met the mobilization target. Median
PB-CD34+ on day 4 was significantly higher in PEG.
Table. Mobilization outcomes
FIL PEGPN 5 74 N 5 57Day 4 PB-CD34+ 18.1 (+/-19.5) 28.7 (+/-27) 0.01
Patients requiring plerixafor 50 (67.5%) 26 (45.6%) 0.01
Number of days of apheresis 1.62 (+/-0.72) 1.68 (+/-0.65) 0.6
Number of injections 13.1 (+/-3.8) 2.7 (+/-0.9) 0.001
Number of CD34+ cells
collected (x10e6/kg)7.26 (+/-3.99) 7.54 (+/-3.52) 0.6Patients meeting
mobilization target68 (91.9%) 52 (91.2%) 1Mobilization failures (<2 x 10e6
CD34+/kg)1 (1.3%) 1 (1.7%) 1Patients in PEG received fewer subcutaneous injections and
were less likely to require administration of plerixafor. Cohorts
had near identical average number of apheresis sessions and com-
parable CD34+ yield. The estimated cost associated with growth
factor was on average US$3,069 higher in PEG, but it was coun-
terbalanced by an estimated $3,546 saving in plerixafor, resulting
in no significant difference in the estimated overall cost of mobi-
lization. Single administration of pegfilgrastim is associated with
better CD34+ mobilization than daily filgrastim in patients with
MM and LY allowing for effective mobilization with less frequent
use of plerixafor. Pegfilgrastin with patient adapted used of plerix-
afor is a reliable, convenient and cost-neutral strategy for AHSC
mobilization.123
HIGH DOSE CHEMOTHERAPY (HDT) WITH BUSULFAN, MELPHALAN AND
TOPOTECAN FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATION (ASCT) IN PEDIATRIC PATIENTS (pts) WITH HIGH
RISK SOLID TUMORS
Pawlowska, A.B.1, Wolfson, J.A.1, Cheng, J.2, Sorrell, A.1, Sato, J.1,
Anderson, C.1, Hitt, D.1, Suarez, M.1, Forman, S.J.3, Rosenthal, J.1
1City of Hope, Duarte, CA; 2Southern California Kaiser Permanente
Medical Group, Los Angeles, CA; 3City of Hope, Duarte, CA
The prognosis of pts with high risk solid tumors remains poor de-
spite advances in multimodal and high dose radiation and chemo-
therapy.
HDT followed by ASCT appears to provide survival benefit to
a select group of pts. We hypothesize that patients with chemo-sen-
sitive solid tumors with poor risk features at diagnosis or with recur-
rent metastatic disease will have lower morbidity and improved
survival with a conditioning regimen using a novel combination of
busulfan, melphalan and topotecan (B-M-T) followed by ASCT.
In this pilot study pts received topotecan continuous infusion in
combination with busulfan (pharmacokinetics (PK) based dose ad-
justment) and melphalan. The primary outcome of interest was the
toxicity of combined HDT with B-M-T. Secondary objectives
were to evaluate engraftment, survival and PK of busulfan and top-
otecan. Twenty-two patients aged 2.2-27 years (median 8.8 yrs)
were treated on the B-M-T protocol at City of Hope from 5/2007
to 4/2011. Diagnoses included Ewing sarcoma (n 5 8), neuroblas-
toma (n5 7),Wilms (n5 3), rhadbomyosarcoma (n5 3) andmedul-
loblastoma (n 5 1). Seven pts were in complete remission, while 15
S250 Poster Session Idemonstrated a partial response at the time of transplant. The con-
ditioning was tolerated well with no treatment related mortality
(TRM) within 100 days and no grade 4 toxicities. All pts developed
grade 1-3mucositis, while 13 reported diarrhea (7 pts grade 3) and 21
developed liver toxicity (transaminitis and/or bilirubin elevation); 2
pts with grade 3. Four pts had grade 3 lung toxicities and 1 pt grade
3 colitis. All pts engrafted: ANC.500 achieved on day 8-17 (median
10); platelets .25,000 on day 11-58 (median 18); platelets .50,000
on day 14-119 (median 23). Overall 1-yr survival is 95% (1 pt died
306 days post transplant); 3 year survival is 72%. All deaths were re-
lated to a disease recurrence: two pts with Ewing sarcoma, 2 with
rhabdomyosarcoma, and one each with neuroblastoma, Wilms and
medullodlastoma.
These data suggest that the B-M-T preparative regimen fol-
lowed by an ASCT was tolerated well without unexpected or se-
vere toxicities; pts had prompt engraftment and 0% TRM. The
survival data are encouraging compared to historical data. This
novel conditioning regimen with a favorable toxicity profile can
be used in the future as a platform for gene therapy, immune-
based cellular therapies or to intensify local control with prompt
administration of intensity modulated radiation therapy (IMRT)
such as helical-tomotherapy.
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RISK FACTORS AND CLINICAL FEATURES OF AUTOLOGOUS GRAFT-VER-
SUS-HOST DISEASE/ENGRAFTMENT SYNDROME AFTER AUTOLOGOUS
HEMATOPOIETIC CELL (HCT) TRANSPLANTATION
Cornell, R.F.1, Thompson, J.2, Drobyski, W.R.1, Fenske, T.S.1,
Horowitz, M.M.3, Palmer, J.M.1, Pasquini, M.C.3, Saad, A.A.1,
Rizzo, J.D.3, Saber, W.3, Zhang, M.-J.2, Zhong, X.3, Hari, P.1 1Medical
College ofWisconsin,Milwaukee,WI; 2Medical College ofWisconsin,Mil-
waukee, WI; 3Medical College of Wisconsin, Milwaukee, WI
Engraftment syndrome (ES) is a complication after HCT. Au-
tologous graft-versus-host disease (AGVHD) a more severe and
potentially life-threatening problem that sometimes follows ES.
The etiology for these complications remains elusive. We ana-
lyzed 315 HCT recipients for multiple myeloma (MM, n 5
210), non Hodgkin lymphoma (NHL, n 5 53), Hodgkin lym-
phoma (HL, n 5 24) and other diseases (n 5 28) to evaluate
the clinical features, frequency, risk factors and outcomes of ES/
AGVHD. ES was defined by the Spitzer and Maiolino criteria.
AGVHD was diagnosed by clinical criteria and all cases confirmed
by biopsy. ES occurred in 75 (24%) patients and 24 (7.6%) had
AGVHD (site: GI n 5 22; skin n 5 4; liver n 5 1). Diarrhea
was the most common manifestation (86%) followed by fever
(59%), skin rash (56%) and LFT abnormalities (30%). Median
time to onset of ES/AGVHD symptoms was 12 days after
HCT. To determine factors which predisposed patients to ES/
AGVHD we examined age, sex, ISS stage, conditioning regimen,
disease type, prior chemotherapy exposure, growth factor exposure
and CD34+ cell count in a multivariate model. Patients with ES/
AGVHD had prolonged hospital stays (p\0.0001). Most AGVHD
patients required higher dose and exposure to corticosteroids
(96%) compared with those with ES (61%) p\0.0001.
By univariate analysis, older age, MM and exposure to bortezomib
or lenalidomide were more likely to develop ES or AGVHD (p 5
0.0006). See Table 1.
Inmultivariatemodels,MMwasmost strongly associated with de-
velopment of ES/AGVHD (p\0.0001) compared to lymphoma or
other diseases. Higher stage MM (ISS III; p 5 0.0177) and the use
of thalidomide, lenalidomide or bortezomib prior to HCT (p 5
0.0009) were associated with development of ES/AGVHD. At me-
dian follow-up of 28 months, there was no difference in overall sur-
vival.
In conclusion, these data demonstrate that ES and AGVHD are
relatively common complications after HCT, occurring in about
one-third of patients. Affected patients had diarrhea, non-infectious
fevers, longer hospitalization and increased morbidity. Early recog-
nition of these conditions is important to initiate appropriate treat-
ment and avoid unnecessary complications. The vast majority were
successfully treated with a short course of corticosteroids. In the
era of immunomodulatory drugs and bortezomib for MM, these
data suggest that the underlying biology of MM and modern treat-
ments may predispose patients to development of these conditions
in the early engraftment period.Table 1. Characteristics of patients without ES/AGVHD vs.
patients with ES/AGVHD
Patient No ES/ ES/ P-value P-valueCharacteristics AGVHD AGVHD (Univariate) (Multivariate)Number of patients 216 99Age at transplant,
median (range), years58 (18-79) 61 (26-77) 0.0006GenderMale 138 (64) 56 (57) 0.2148DiseaseMultiple Myeloma 123 (57) 87 (88) <0.0001 <0.0001Lymphoma 66 (31) 11 (11) 0.0002Others 27 (12) 2 (2) 0.0026International StageStage III 12 (6) 21 (21) <0.0001 <0.0047Chemotherapy <0.0009Prior Lenalidomide 36 (17) 30 (30) 0.0058Prior Bortezomib 84 (39) 64 (65) <0.0001Prior Thalidomide 19 (9) 15 (15) 0.0915Other prior chemotherapy 115 (72) 64 (65) 0.0230ConditioningMel 125 (56) 82 (83) <0.0001BEAM 72 (33) 9 (9) <0.0001CyTBI 3 (1) 2 (2) 0.6512Growth FactorPegfilgrastim 22 (10) 9 (9) 0.7921Filgrastim 192 (89) 88 (89) 0.9999CellularityCD34+ cell/kg, median X106 5 5 0.4149Median days from
transplant to
discharge (range)15 (7-94) 17 (6-164) <0.0001OutcomesOverall survival
(prob 95% CI)At 12 months 86 (80-90) 89 (79-94) 0.839At 36 months 74 (67-80) 82 (70-90) 0.182Death rate
(point estimate)At 100 days 4 (2-7) 3 (2-7)125
OUTCOMES OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PHILA-
DELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Keyzner, A., Donahue, L.L., Bayer, R.L. Hofstra University School of
Medicine - North Shore LIJ Health System, Lake Success, NY
Purpose: Patients with Ph+ALL have very poor outcomes in the ab-
sence of allogeneic stem cell transplant. Allogeneic stem cell trans-
plantation, even with reduced intensity preparative regimens, is
associated with higher rates of mortality and morbidity as compared
to conventional chemotherapy or autologous stem cell transplanta-
tion. HLA matched donors are not always available and certain pa-
tients may not be good candidates for this procedure. The best
treatment alternatives to allogeneic stem cell transplant are not
known in the current era of tyrosine kinase inhibitor (TKI) use.
Autologous stem cell transplantation has been attempted in the
pre-TKI era with very limited success. We report outcomes of eight
patients with Ph+ALL treated with autologous stem cell transplanta-
tion in combination with TKI use pre and post transplant.
Method/Results:We treated 8 patients with Ph+ ALL, between the
years of 2004 to 2010, who did not have an available HLA-compat-
ible donor with autologous stem cell transplantation. All patients un-
derwent standard induction chemotherapy for ALL in combination
with Imatinib. One patient who did not achieve complete molecular
remission following induction chemotherapy with Imatinib received
Dasatinib. Complete molecular remission was documented in all pa-
tients prior to peripheral blood stem cell (PBSC) mobilization with
VP-16/Ara-C. Seven patients received TBI/Cytoxan/Etoposide as
their preparative regimen and one patient received Busulfan/Cy-
toxan. All but one patient engrafted neutrophils at median 10 days
(range 9-56) and platelets at median 21 days (range 9-.365). One pa-
tient died prior to engraftment. Following recovery of counts
